Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History

JAMA Cardiol. 2020 Sep 1;5(9):1066-1067. doi: 10.1001/jamacardio.2020.1738.

Authors

Ahmad Masri^{1

2}, Hongya Chen^{1

2}, Catherine Wong^{1

2}, Katherine L Fischer^{1

2}, Chafic Karam^{2

3}, Walid F Gellad⁴, Stephen B Heitner^{1

2}

Affiliations

¹ The Knight Cardiovascular Institute, Oregon Health & Science University, Portland.
² Oregon Health & Science University Amyloidosis Center, Portland.
³ Department of Neurology, Oregon Health & Science University, Portland.
⁴ Center for Pharmaceutical Policy and Prescribing, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

Abstract

This economic evaluation study examines the authors’ experience of prescribing tafamidis in terms of their cost and the insurance status of patients.

Publication types

Review

MeSH terms

Benzoxazoles / pharmacology*
Cardiovascular Diseases / drug therapy*
Drug Prescriptions / statistics & numerical data*
Humans

Substances

Benzoxazoles
tafamidis